Daniel R. Carrizosa
Experienced in Pancreatic Islet Cell Tumor

Dr. Daniel R. Carrizosa

Hematology | Oncology
1021 Morehead Medical Drive, Building 2, Suite 30500, 
Charlotte, NC 
On Staff At
Accepting New Patients
Offers Telehealth
Experienced in Pancreatic Islet Cell Tumor
1021 Morehead Medical Drive, Building 2, Suite 30500, 
Charlotte, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Carrizosa is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Carrizosa is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Lung Cancer, Nasopharyngeal Carcinoma, Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Carrizosa is currently accepting new patients.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
The University Of North Carolina
Residency
The University of North Carolina, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Medicine, Medical Oncology
Fellowships
The University of North Carolina, Hematology/Oncology
Hospital Affiliations
Carolinas Medical Center/behav Health
Novant Health Presbyterian Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Atrium Health Levine Cancer Institute (Thoracic-Pulmonary)
1021 Morehead Medical Drive, Building 2, Suite 30500, Charlotte, NC 28204

Additional Areas of Focus

Dr. Carrizosa has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer
Prostate Cancer
B-Cell Lymphoma
Interstitial Lung Disease
Colorectal Cancer
Leukemia
Multiple Myeloma
Adult T-Cell Leukemia
Liver Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Carboplatin
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
View 6 Less Clinical Trials

26 Total Publications

Evaluation of End-of-Life Quality Care Between American Indian and White North Carolina Decedents Diagnosed With Lung Cancer, 2003-2020.
Evaluation of End-of-Life Quality Care Between American Indian and White North Carolina Decedents Diagnosed With Lung Cancer, 2003-2020.
Journal: JCO oncology practice
Published: January 13, 2025
Similar Doctors
Aakanksha Asija
Experienced in Pancreatic Islet Cell Tumor
Dr. Aakanksha Asija
Oncology | Hematology
Experienced in Pancreatic Islet Cell Tumor
Dr. Aakanksha Asija
Oncology | Hematology

Novant Health Cancer Institute - Ballantyne

10905 Providence Rd W Ste 150, Ste 150, 
Charlotte, NC 
 (10.7 miles away)
980-302-7120
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aakanksha Asija is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Asija has been practicing medicine for over 20 years and is rated as an Advanced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Lung Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC).

John S. Salmon
Experienced in Pancreatic Islet Cell Tumor
Dr. John S. Salmon
Hematology | Oncology
Experienced in Pancreatic Islet Cell Tumor
Dr. John S. Salmon
Hematology | Oncology

Atrium Health Levine Cancer Institute

101 E. W.T. Harris Blvd., Building 5000, Suite 5500, 
Charlotte, NC 
 (8.6 miles away)
704-863-6160
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Salmon is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Salmon is rated as an Advanced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Pancreatic Cancer, Paget Disease of the Breast, Familial Pancreatic Cancer, and Colorectal Cancer. Dr. Salmon is currently accepting new patients.

Experienced in Pancreatic Islet Cell Tumor
Dr. Alfred J. Newman
Oncology | Hematology Oncology | Hematology
Experienced in Pancreatic Islet Cell Tumor
Dr. Alfred J. Newman
Oncology | Hematology Oncology | Hematology

The Presbyterian Hospital

1700 Matthews Township Pkwy, 
Matthews, NC 
 (9.2 miles away)
980-302-7010
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alfred Newman is an Oncologist and a Hematologist Oncology provider in Matthews, North Carolina. Dr. Newman is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Paget Disease of the Breast. Dr. Newman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carrizosa's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile